Tesamorelin / ipamorelin stack: what's in it
- 3 sources
- How we source
- We don't sell peptides. We never link "research use only" sellers.
The short answer
Tesamorelin / ipamorelin stack combines Tesamorelin and Ipamorelin.
What it is
GH-axis stack (GHRH analog + ghrelin agonist).
What people look into
Weight, muscle and exercise, aging, sleep
Results for one compound don't tell you what the two do together.
The parts
FDA-approved (Rx)
WADA 2026: S2.2.4
Tesamorelin Papers on animals 1 Lab-dish (cell) papers 1 Papers PubMed tags as about people 54 Registered trials (ClinicalTrials.gov) 17 of 23 search results name Tesamorelin Randomized trials in people 21 Not FDA-approved
WADA 2026: S2.2.4
Ipamorelin Papers on animals 20 Lab-dish (cell) papers 1 Papers PubMed tags as about people 22 Registered trials (ClinicalTrials.gov) 2 of 3 search results name Ipamorelin Randomized trials in people 2
Bars are counts of papers or trials; a longer bar means more studies, not better results. Study counts auto-counted from PubMed tags and ClinicalTrials.gov in the Ellum research database, as of October 6, 2026 (not reviewed; a paper can carry more than one tag). Papers PubMed tags as about people: includes reviews and case reports; not randomized trials. All bars share one scale. Each count is for that part alone.
What's in it
Tesamorelin is a lab-made form of the hormone that tells the body to make growth hormone.[1] Stimulates the pituitary to release growth hormone.[1]
Ipamorelin is a short chain of five amino acids that is made in a lab.[2] Ghrelin-receptor agonist that releases GH.[2]
Regulatory status by component
Not FDA-approved How we label status
- As of October 4, 2026, Tesamorelin is an FDA-approved prescription drug for excess abdominal fat in HIV-associated lipodystrophy. See Tesamorelin in the Index →
- As of October 4, 2026, Ipamorelin is not FDA-approved for any use and is not on FDA's 503A bulks list. See Ipamorelin in the Index →
Status as of October 4, 2026
- As a combination
- No category as a combination (see components)
Timeline
Scroll sideways to see all columns.
| Date | What happened | Source |
|---|---|---|
| FTC notice in the Federal Register of the HISA Anti-Doping and Medication Control Rule (horseracing) lists ipamorelin and tesamorelin as banned substances. | Federal Register, event of October 28, 2022, on federalregister.gov | |
| FTC notice in the Federal Register of the HISA Anti-Doping and Medication Control Rule (horseracing) lists ipamorelin and tesamorelin as banned substances. | Federal Register, event of January 26, 2023, on federalregister.gov | |
| FDA warning letter to an online seller names a product described as a blend of tesamorelin and ipamorelin among products FDA states are unapproved new drugs. | FDA, event of August 24, 2026, on fda.gov | |
| FDA warning letter to an online seller quotes the seller's webpage describing a product as a blend of tesamorelin and ipamorelin. | FDA, event of August 24, 2026, on fda.gov |
Get updates on Tesamorelin / ipamorelin stack
The research on Tesamorelin / ipamorelin stack
Key facts
Also known as: tesamorelin ipamorelin, tesa ipa, tesa/ipa, tesa ipa blend
- Parts
- Tesamorelin and Ipamorelin
- Route
- injectable
References
Status sources
Sources as of October 4, 2026
What this doesn’t establish
Results for one compound don't tell you what the two do together.